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Abstract
Interpretation of variants present in complete genomes or exomes reveals
numerous sequence changes, only a fraction of which are likely to be
pathogenic. Mutations have been traditionally inferred from allele frequencies
and inheritance patterns in such data. Variants predicted to alter mRNA splicing
can be validated by manual inspection of transcriptome sequencing data,
however this approach is intractable for large datasets. These abnormal mRNA
splicing patterns are characterized by reads demonstrating either exon
skipping, cryptic splice site use, and high levels of intron inclusion, or
combinations of these properties. We present, Veridical, an  method forin silico
the automatic validation of DNA sequencing variants that alter mRNA splicing.
Veridical performs statistically valid comparisons of the normalized read counts
of abnormal RNA species in mutant versus non-mutant tissues. This leverages
large numbers of control samples to corroborate the consequences of
predicted splicing variants in complete genomes and exomes.
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Introduction
DNA variant analysis of complete genome or exome data has typi-
cally relied on filtering of alleles according to population frequency 
and alterations in coding of amino acids. Numerous variants of 
unknown significance (VUS) in both coding and non-coding gene 
regions cannot be categorized with these approaches. To address 
these limitations, in silico methods that predict biological impact of 
individual sequence variants on protein coding and gene expression 
have been developed, which exhibit varying degrees of sensitivity 
and specificity1. These approaches have generally not been capable 
of objective, efficient variant analysis on a genome-scale.
Splicing variants, in particular, are known to be a significant cause 
of human disease2–5 and indeed have even been hypothesized to 
be the most frequent cause of hereditary disease6. Computational 
identification of mRNA splicing mutations within DNA sequenc-
ing (DNA-Seq) data has been implemented to varying degrees of 
sensitivity, with most software only evaluating conservation solely 
at the intronic dinucleotides adjacent to the junction (i.e.7). Other 
approaches are capable of detecting significant mutations at other 
positions with constitutive, and in certain instances, cryptic, splice 
sites5,8,9 which can result in aberrations in mRNA splicing. Presently, 
only information theory-based mRNA splicing mutation analysis 
has been implemented on a genome scale10. Splicing mutations can 
abrogate recognition of natural, constitutive splice sites (inactivat-
ing mutation), weaken their binding affinity (leaky mutation), or 
alter splicing regulatory protein binding sites that participate in 
exon definition. The abnormal molecular phenotypes of these muta-
tions comprise: (a) complete exon skipping, (b) reduced efficiency 
of splicing, (c) failure to remove introns (also termed intron reten-
tion or intron inclusion), or (d) cryptic splice site activation, which 
may define abnormal exon boundaries in transcripts using non- 
constitutive, proximate sequences, extending or truncating the exon. 
Some mutations may result in combinations of these molecular 
phenotypes. Nevertheless, novel or strengthened cryptic sites can 
be activated independently of any direct effect on the corresponding 
natural splice site. The prevalence of these splicing events has been 
determined by ourselves and others5,11–13. The diversity of possible 
molecular phenotypes makes such aberrant splicing challenging to 
corroborate at the scale required for complete genome (or exome) 
analyses. This has motivated the development of statistically robust 
algorithms and software to comprehensively validate the predicted 
outcomes of splicing mutation analysis.
Putative splicing variants require empirical confirmation based on 
expression studies from appropriate tissues carrying the mutation, 
compared with control samples lacking the mutation. In mutations 
identified from complete genome or exome sequences, correspond-
ing transcriptome analysis based on RNA sequencing (RNA-Seq) 
is performed to corroborate variants predicted to alter splicing. 
Manually inspecting a large set of splicing variants of interest with 
reference to the experimental samples’ RNA-Seq data in a program 
like the Integrative Genomics Viewer (IGV)14, or simply performing 
database searches to find existing evidence would be time-consuming 
for large-scale analyses. Checking control samples would be required 
to ensure that the variant is not a result of alternative splicing, but is 
actually causally linked to the variant of interest. Manual inspection 
of the number of control samples required for statistical power to 
verify that each displays normal splicing would be laborious and 
does not easily lend itself to statistical analyses. This may lead to 
either missing contradictory evidence or to discarding a variant due 
to the perceived observation of statistically insignificant altered 
splicing within control samples. In addition, a list of putative splic-
ing variants returned by variant prediction software can often be 
extremely large. The validation of such a significant quantity of vari-
ants may not be feasible, for example, in certain types of cancer, in 
instances where the genomic mutational load is high and only man-
ual annotation is performed. We have therefore developed Veridical, 
a software program that automatically searches all given experi-
mental and control RNA-Seq data to validate DNA-derived splicing 
variants. When adequate expression data are available at the locus 
carrying the mutation, this approach reveals a comprehensive set 
of genes exhibiting mRNA splicing defects in complete genomes 
and exomes. Veridical and its associated software programs are 
available at: www.veridical.org.
Methods
The program Veridical was developed to allow high-throughput 
validation of predicted splicing mutations using RNA sequencing 
data. Veridical requires at least three files to operate: a DNA vari-
ant file containing putative mRNA splicing mutations, a file list-
ing of corresponding transcriptome (RNA-Seq) BAM files, and a 
file annotating exome structure. A separate file listing RNA-Seq 
BAM files for control samples (i.e. normal tissue) can also be pro-
vided. Here, we predict mutations in a set of breast tumours which 
are validated with RNA-Seq data from the same individuals, with 
RNA-Seq data from normal breast tissues as controls. However, in 
principle, potential splicing mutations for any disease state with 
available RNASeq data can be investigated. In each tumour, every 
variant is analyzed by checking the informative sequencing reads 
from the corresponding RNA-Seq experiment for non-constitutive 
splice isoforms, and comparing these results with the same type of 
data from all other tumour and normal samples that do not carry the 
variant in their exomes.
Veridical concomitantly evaluates control samples, providing for 
an unbiased assessment of splicing variants of potentially diverse 
phenotypic consequences. Note that control samples include all 
non-variant containing files, as well any normal samples provided. 
Maximizing the set of control samples, while computationally 
more expensive, increases the statistical robustness of the results 
obtained.
For each variant, Veridical directly analyzes sequence reads aligned 
to the exons and introns that are predicted to be affected by the 
genomic variant. We elected to avoid indirect measures of exon 
skipping, such as loss of heterozygosity in the transcript, because 
of the possibility of confusion with other molecular etiologies (i.e. 
deletion or gene conversion), unrelated to the splicing mutations. 
The nearest natural site is found using the exome annotation file 
provided, based upon the directionality of the variant, as defined 
within Table 1. The genomic coordinates of the neighboring exon 
boundaries are then found and the program proceeds, iterating over 
all known transcript variants for the given gene. A diagram of this 
procedure is provided in Figure 1. The variant location, C, is spe-
cifically referring to the, variant-induced, location of the predicted 
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mRNA splice site, which is often proximate to, but distinct from the 
coordinate of the actual genomic mutation itself.
The program uses the BamTools API15 to iterate over all of the reads 
within a given genomic region across experimental and control sam-
ples. Individual reads are then assessed for their corroborating value 
towards the analysis of the variant being processed, as out-
lined in the flowchart in Figure 2. Validating reads are based on 
whether they alter either the location of the splice junction (i.e. 
junction-spanning) or the abundance of the transcript, particu-
larly in intronic regions (i.e. read-abundance). Junction-span-
ning reads contain DNA sequences from two adjacent exons or 
are reads that extend into the intron. These reads directly show 
whether the intronic sequence is removed or retained by the 
spliceosome, respectively. Read-abundance validated reads are 
based upon sequences predicted to be found in the mutated tran-
script in comparison with sequences that are expected to be ex-
cised from the mature transcript in the absence of a mutation. 
Both types of reads can be used to validate cryptic splicing, exon 
skipping, or intron inclusion. A read is only said to corroborate 
cryptic splicing if and only if the variant under consideration is 
expected to activate cryptic splicing. Junction-spanning, cryptic 
splicing reads are those in which a read is exactly split from the 
cryptic splice site to the adjacent exon junction. For read-abundance 
cryptic splicing, we define the concept of a read fraction, which 
is the ratio of the number of reads corroborating the cryptically 
spliced isoform and the number of reads that do not support the 
use of the cryptic splice site (i.e. non-cryptic corroborating) in the 
same genomic region of a sample. Cryptic corroborating reads are 
those which occur within the expected region where cryptic splic-
ing occurs (i.e. spliced-in regions). This region is bounded by the 
variant splice site location and the adjacent (direction depend-
ent) splice junction. Non-cryptic corroborating reads, which we 
also term “anti-cryptic” reads, are those that do not lie within this 
region, but would still be retained within the portion that would be 
excised, had cryptic splicing occurred. To identify instances of exon 
skipping, Veridical only employs junction-spanning reads. A read 
is considered to corroborate exon skipping if the connecting read 
segments are split such that it connects two exon boundaries, skip-
ping an exon in between. A read is considered to corroborate intron 
inclusion when the read is continuous and either overlaps with the 
intron-exon boundary (and is then said to be junction-spanning) or 
if the read is within an intron (and is then said to be based upon 
read-abundance).
We proceed to formalize the above descriptions as follows. A given 
read is denoted by r, with start and end coordinates (r
s
, r
e
), if the read 
is continuous, as diagrammed within Figure 1(c), or otherwise, with 
start and end coordinate pairs, (r
s1
, r
e1
) and (r
s2,
 r
e2
), as diagrammed 
within Figure 1(d). Let l be the length of the read. The set ζ denotes 
the totality of validating reads. The criterion for r ∈ ζ is detailed 
below. It is important to note that validating reads are necessary 
but not sufficient to validate a variant. Sufficiency is achieved only 
if the number of validating reads is statistically significant relative 
to those present in control samples. ζ itself is partitioned into three 
sets: ζ
c
, ζ
e
, and ζi for evidence of cryptic splicing, exon skipping, 
and intron inclusion, respectively. We allow partitions to be empty. 
Let S denote the relevant splice junctions as defined by Figure 1 and 
Table 1. Without loss of generality, we consider only the red (i.e. 
direction is right) set of labels within Figure 1(b). Then the (splice 
consequence) partitions of ζ are given by:
r ∈ ζ
c
 ⇔ variant is cryptic ∧ r
s2
 – r
e1
 = C – S ∨ (r
s
 > A ∧ r
e
 < S)
r ∉ ζ
c
 ∧ variant is cryptic ∧ ¬ ( r
s2
 – r
e1
 = C – S) ⇒ r ∈ anticryptic
r ∈ ζ
e
 ⇔ (r
e1
= A ∧ r
s2
= B)
Table 1. Definitions used within Veridical to determine the 
direction in which reads are checked. A and B represent natural 
site positions, defined in Figure 1(b).
 Pertinent Splice Site
A B Strand Direction
Exonic Donorα + →
Exonic Donorα - ←
Intronic Acceptorβ + ←
Intronic Acceptorβ - →
                   
α – 5′ splice site  β – 3′ splice site
(B) Veridical searches for validating reads between A and 
 B  (B site left            of A             B        D.  B site right 
 ) of A          B     E).   
(D) An example of a discontinous read. The start and end
coordinates of the read’s two portions are denoted by (s1,e1)
and (s2,e2).   
(C) An example of a continous read. The  read start coordi-
nate is denoted by S and its end coordinate by E.
(A) All reads overlapping or between D or E are extracted
from the BAM files (D > E         swap D and E ). 
Figure 1. A diagram portraying the definitions used within Veridical 
to specify genic variant position and read coordinates. We employ 
the same conventions as IGV14. Blue lines denote genes, wherein 
thick lines represent exons and thin lines represent introns. Grey 
lines denote reads, wherein thick lines denote a read mapping to 
some particular location in the genome and thin lines represent 
connecting segments of reads that are split across spliced-in 
regions (i.e. exons or included introns).
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Figure 2. The algorithm employed by Veridical to validate variants. Refer to Table 1 for definitions concerning direction and Figure 1 for 
variable definitions.
Page 5 of 23
F1000Research 2014, 3:8 Last updated: 18 MAR 2014
r ∈ ζi ⇔ (A ∈ [rs, re] ∨ B ∈ [rs, re]) ∨ [(A ∉ [rs, re] ∧ B ∉ [rs, re]) 
∧ (r
s
 < A – l ∧ r
e
 > B ∧ r ∉ (A, B))]
We separately partition ζ by its evidence type, the set of junction-
spanning reads, δ and read-abundance reads, α, as follows:
r ∈ δ ⇔ (A ∈ [r
s
, r
e
] ∨ B ∈ [r
s
, r
e
]) ∨ [r ∈ ζ
c
 ∧ r
s2 – re1 = C – S]. 
r ∈ α ⇔ r ∉ δ
Once all validating reads are tallied for both the experimental and 
control samples, a p-value is computed. This is determined by com-
puting a z-score upon Yeo-Johnson (YJ)16 transformed data. This 
transformation, shown in Equation 1, ensures that the data is suf-
ficiently normally distributed to be amenable to parametric testing.
  
 
2
( 1) 1 if 0 0
log( 1) if 0 0
( , ) (1)
( 1) 1
if  < 0 2
2
log( 1) if  < 0 2
x x
x x
x
x x
x x
λ
λ
λ
λ
λ
ψ λ
λ
λ
λ
−
 + − ≥ ∧ ≠
+ ≥ ∧ =
= 
− + −
− ∧ ≠
−
− − + ∧ =
The transform is similar to the Box-Cox power transformation, but 
obviates the requirement of inputting strictly positive values and 
has more desirable statistical properties. Furthermore, this transfor-
mation allowed us to avoid the use of non-parametric testing, which 
has its own pitfalls regarding assumptions of the underlying data 
distribution17. We selected λ = 1–2, because Veridical’s untransformed 
output is skewed left, due to their being, in general, less validating 
reads in control samples and the fact that there are, by design, vastly 
more control samples than experimental samples. We found that 
this value for λ generally made the distribution much more normal.
A comparison of the distributions of untransformed and trans-
formed data is provided in Figure S1. We were not concerned 
about small departures from normality as a z-test with a large 
number of samples is robust to such deviations18. It is important 
to realize, therefore, that the p-values given by Veridical are much 
more robust when the program is provided with a large number of 
samples.
Thus, we can compute the p-value of the pairwise unions of the two 
sets of partitions of ζ, except the irrelevant ζ
e
 ∪ α = ∅. We only 
provide p-values for these pairwise unions and do not attempt to 
provide p-values for the partitions for the different consequences 
of the mutations on splicing. While such values would be useful, 
we do not currently have a robust means to compute them. Our 
previous work provides guidance on interpretation of splicing mu-
tation outcomes3–5,10. Thus for ζ
x
 ∈ {ζ
c
, ζ
e
, ζi}, let ΦZ(z) represent the 
cumulative distribution function of the one-sided (right-tailed — 
i.e. P[X > x]) standard normal distribution. Let N represent the total 
number of samples and let V represent the set of all ζ
x
 validations, 
across all samples. Then:
 
1 2
1
1 ( )
| ζ | 1( ( , ))
2
N
j N
j
j
j
V
V V
N N
xz p z
µ σ
µ ψ
σ
=
=
= = −
−
= = Φ
∑
∑
The program outputs two tables, along with summaries thereof. 
The first table lists all validated read counts across all categories 
for experimental samples, while the second table does the same for 
the control samples. P-values are shown in parentheses within the 
experimental table, which refer to the column-dependent (i.e. the 
category is given in the column header) p-value for that category 
with respect to that same category in control samples. The program 
produces three files: a log file containing all details regarding vali-
dated variants, an output file with the programs progress reports and 
summaries, and a filtered validated variant file. The filtered file con-
tains all validated variants of statistical significance (set as p < 0.05, by 
default), defined as variants with one or more validating read cat-
egories which achieve statistical significance in a relevant category 
(i.e. a cryptic variant for which p = 0.04 in the junction-spanning 
cryptic column would meet this criteria).
We elected to use RefSeq19 genes for the exome annotation, as op-
posed to, the more permissive exome annotation sets, UCSC Known 
Genes20 or Ensembl21. The large number of transcript variants within 
Ensembl, in particular, caused many spurious intron inclusion vali-
dation events. This occurred because reads were found to be intronic 
in many cases, when in actuality they were exonic with respect to 
the more common transcript variant. In addition, the inclusion of the 
large number of rare transcripts in Ensembl significantly increased 
program runtime and made validation events much more challenging 
to interpret unequivocally. The use of RefSeq, which is a conserva-
tive annotation of the human exome, resolves these issues.
We also provide an R program22 which produces publication quality 
histograms displaying embedded Q-Q plots and p-values, to evaluate 
for normality of the read distribution and statistical significance, 
respectively. The R program performs the YJ transformation as 
implemented in the car package23. The histograms generated by 
the program use the Freedman-Draconis24 rule for break determi-
nation, and the Q-Q plots use algorithm Type 8 for their quantile 
function, as recommended by Hyndman and Fan25. Lastly, a Perl 
program was implemented to automatically retrieve and correctly 
format an exome annotation file from the UCSC database20 for use 
in Veridical. All data uses hg19/GRCh37, however when new ver-
sions of the genome become available, this program can be used to 
update the annotation file.
Results
Veridical validates predicted mRNA splicing mutations using high-
throughput RNA sequencing data. The performance of the software 
is affected by the number of predicted splicing mutations, the num-
ber of abnormal samples containing mutations and control samples 
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and the corresponding RNA-Seq data for each type of sample. 
Veridical has the ability to analyze approximately 3000 variants in 
approximately 4 hours assuming an input of 100 BAM files of RNA-
Seq data. The relationship between time and numbers of BAM files 
and variants are plotted in Figure 3 for a 2.27 GHz processor. Veridi-
cal uses memory in linear proportion to the number and size of the 
input BAM files. In our tests, using RNA-Seq BAM files with an 
average size of approximately 6 GB, Veridical used approximately 
0.7 GB for ten files to 1 GB for 100 files. Currently, splicing con-
sequences that are reported include intron inclusion, exon skipping, 
and cryptic splicing, which are validated through junction-spanning 
reads, or based on read-abundance in the region circumscribing the 
variant (see Methods for details). For example, a cryptic splicing 
junction-spanning read will show that the mRNA contains a trun-
cated or extended exon at the predicted location, which is directly 
attached to the sequence of the corresponding adjacent exon. For 
mutations that alter read-abundance, each read within the genomic 
location assessed (i.e. intron for intron inclusion) is counted for the 
variant-containing samples and then compared with the number of 
reads in the control files. For each input variant, Veridical outputs 
the number of validating reads (i.e. RNA-Seq reads which corrobo-
rate the predicted splicing consequence) for a given splice conse-
quence within the variant-containing tumour samples and within 
control samples (i.e. non-variant containing tumour samples and 
normal samples). The program provides read counts for the different 
categories for all experimental and control samples as tab-delimited 
tables, along with the relevant p-values, indicating the statistical 
probability that the predicted mutation exhibits a normal expres-
sion pattern.
We demonstrate how Veridical and its associated R program are 
used to validate predicted splicing mutations in somatic breast 
cancer. Each example depicts a particular variant-induced splicing 
consequence, analyzed by Veridical, with its corresponding signifi-
cance level. The relevant primary RNA-Seq data are displayed in 
IGV, along with histograms and Q-Q plots showing the read dis-
tributions for each example. The source data are obtained from 
controlled-access breast carcinoma data from The Cancer Genome 
Atlas (TCGA)28. Tumour-normal matched DNA sequencing data 
from the TCGA consortium was used to predict a set of splicing 
mutations, and a subset of corresponding RNA sequencing data 
was analyzed to confirm these predictions with Veridical. The fol-
lowing examples demonstrate the utility of Veridical to identify 
potentially pathogenic mutations from a much larger subset of pre-
dicted variants.
Input, output, and explanatory files for Veridical
5 Data Files
http://dx.doi.org/10.6084/m9.figshare.894971
Leaky mutations are those variants that reduce, but not abolish, the 
spliceosome’s ability to recognize the intron/exon boundary3. This 
can lead to the mis-splicing (intron inclusion and/or exon skipping) 
of many but not all transcripts. An example of a predicted leaky 
mutation (chr5:162905690 G>T) in the HMMR gene in which both 
junction-spanning exon skipping (p < 0.01) and read-abundance-
based intron inclusion (p = 0.04) are observed is provided within 
Figure 4. We predict this mutation to be leaky because its final Ri 
exceeds 1.6 bits — the minimal individual information required 
to recognize a splice site and produce correctly spliced mRNA4. 
Indeed, the natural site, while weakened by 2.16 bits, remains 
strong — 10.67 bits. This prediction is validated by the variant-
containing sample’s RNA-Seq data (Figure 4), in which both exon 
skipping (5 reads) and intron inclusion (14 reads) are observed, 
along with 70 reads portraying wild-type splicing. Only a single 
normally spliced read contains the G→T mutation. These results 
are consistent with an imbalance of expression of the two alleles, 
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Figure 3. Profiling data for Veridical runtime. Tests were conducted upon an Intel Xeon @2.27 GHz. Visualizations were generated with R22 
using Lattice26 and Effects27. A surface plot of time vs. numbers of BAM files and variants is provided in (A). Effect plots are given in (B) and 
demonstrate the effects of the numbers of BAM files and variants upon runtime. The effect plots were generated using a linear regression 
model (R 2  = 0.7525).
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as expected for a leaky variant. Figure 5 shows that for the dis-
tribution of read-abundance-based intron inclusion is statistically 
significant (p = 0.04).
Variants that inactivate splice sites have negative final Ri values3 
with only rare exceptions4, indicating that splice site recognition 
is essentially abolished in these cases. We present the analysis of 
two inactivating mutations within the PTEN and TMTC2 genes 
from different tumour exomes, namely: chr10:89711873 A>G 
and chr12:83359523 G>A, respectively. The PTEN variant dis-
plays junction-spanning exon skipping events (p < 0.01), while the 
TMTC2 gene portrays both junction-spanning and read-abundance-
based intron inclusion (both splicing consequences with p < 0.01). 
In addition, all intron inclusion reads in the experimental sample 
contain the mutation itself, while only one such read exists across 
all control samples analyzed (p < 0.01). The PTEN variant con-
tains numerous exon skipping reads (32 versus an average of 2.466 
such reads per control sample). The TMTC2 variant contains many 
junction-spanning intron inclusion reads with the G→A mutation 
(all of its junction-spanning intron inclusion reads: 22 versus an 
average of 0.002 such reads per control sample). IGV screenshots 
for these variants are provided within Figure 6. This figure also 
shows an example of junction-spanning cryptic splice site activated 
by the mutation (chr1:985377 C>T) within the AGRN gene. The 
concordance between the splicing outcomes generated by these 
mutations and the Veridical results indicates that the proposed 
method detects both mutations that inactivate splice sites and cryp-
tic splice site activation.
(A) (B)
Figure 4. IGV images depicting a predicted leaky mutation (chr5:162905690 G>T) within the natural acceptor site of exon 12 (162905689–
162905806) of HMMR. This gene has four transcript variants and the given exon number pertains to isoforms a and b (reference sequences 
NM_001142556 and NM_012484). RNA-Seq reads are shown in the centre panel. The bottom blue track depicts RefSeq genes, wherein 
each blue rectangle denotes an exon and blue connecting lines denote introns. In the middle panel, each rectangle (grey by default) denotes 
an aligned read, while thin lines are segments of reads split across exons. Red and blue coloured rectangles in the middle panel denote 
aligned reads of inserts that are larger or smaller than expected, respectively. (A) depicts a genomic region of chromosome 5: 162902054–
162909787. The variant occurs in the middle exon. Intron inclusion can be seen in this image, represented by the reads between the first and 
middle exon (since the direction is right, as described within Table 1). These 14 reads are read-abundance-based, since they do not span 
the intron-exon junction. (B) depicts a closer view of the region shown in (A) — 162905660–162905719. The dotted vertical black lines are 
centred upon the first base of the variant-containing exon. The thin lines in the middle panel that span the entire exon fragment are evidence 
of exon skipping. These 5 reads are split across the exon before and after the variant-containing exon, as seen in (A).
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Figure 5. Histogram of read-abundance-based intron inclusion 
with embedded Q-Q plots of the predicted leaky mutation 
(chr5:162905690 G>T) within HMMR, as shown in Figure 4. The 
arrowhead denotes the number of reads (14 in this case) in the 
variant-containing file which is more than observed in the control 
samples (p = 0.04).
Page 8 of 23
F1000Research 2014, 3:8 Last updated: 18 MAR 2014
Figure 6. (A) depicts an inactivating mutation (chr10:89711873 A>G) within the natural acceptor site of exon 6 (89711874–89712016) 
of PTEN. The dotted vertical black line denotes the location of the relevant splice site. The region displayed is 89711004–89712744 on 
chromosome 10. Many of the 32 exon skipping reads are evident, typified by the thin lines in the middle panel that span the entire exon. 
There is also a significant amount of read-abundance-based intron inclusion, shown by the reads to the left of the dotted vertical line. Exon 
skipping was statistically significant (p < 0.01), while read-abundance-based intron inclusion was not (p = 0.53). Panels (B) and (C) depict 
an inactivating mutation (chr12:83359523 G>A) within the natural donor site of exon 6 (83359338–83359523) of TMTC2. (B) depicts a closer 
view (83359501–83359544) of the region shown in (C) and only shows exon 6. Some of the 22 junction-spanning intron inclusion reads can 
be seen. In this case, all of these reads contain the mutation, shown by the green adenine base in each read, between the two vertical dotted 
lines. (C) depicts a genomic region of chromosome 12: 83359221–83360885, TMTC2 exons 6–7. The variant occurs in the left exon. 65 read-
abundance-based intron inclusion can be seen in this image, represented by the reads between the two exons. Panel (D) depicts a mutation 
(chr1:985377 C>T) causing a cryptic donor to be activated within exon 27 (the second from left, 985282–985417) of AGRN. The region 
displayed is 984876–985876 on chromosome 1 (exons 26–29 are visible). Some of the 34 cryptic (junction-spanning) reads are portrayed. 
The dotted black vertical line denotes the cryptic splice site, at which cryptic reads end. Refer to the caption of Figure 4 for IGV graphical 
element descriptions.
Recurrent genetic mutations in some oncogenes have been reported 
among tumours within the same, or different, tissues of origin. 
Common recurrent mutations present in multiple abnormal sam-
ples are recognized by Veridical. This avoids including a variant- 
containing sample among the control group, and outputs the results of 
all of the variant-containing samples. A relevant example is shown 
in Figure 7. The mutation (chr1:46726876 G>T) causes activa-
tion of a cryptic splice site within RAD54L in multiple tumours. 
Upon computation of the p-values for each of the variant-containing 
tumours, relative to all non-variant containing tumours and normal 
controls, not all variant-containing tumours displayed splicing abnor-
malities at statistically significant levels. Of the six variant-containing 
(A) (B)
(C) (D)
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Figure 7. IGV images and their corresponding histograms with embedded Q-Q plots depicting all six variant containing files with a mutation 
(chr1:46726876 G>T) which, in some cases, causes a cryptic donor to be activated within the intron between exons 7 and 8 of RAD54L. 
This results in the extension of the downstream natural donor (the 5´ end of exon 8). This gene has two transcript variants and the given exon 
numbers pertain to isoform a (reference sequence NM_003579). Only samples IV and V have statistically significant intron inclusion relative 
to controls. read-abundance-based intron inclusion can be seen in (A), between the two exons. The region displayed is on chromosome 1: 
46726639–46726976. (B) depicts the corresponding histogram for the 15 read-abundance-based intron inclusion reads (p = 0.05) that are 
present in sample IV. The intron-exon boundary on the right is the downstream natural donor. (C) typifies some of the 13 junction-spanning 
intron inclusion reads that are a direct result of the intronic cryptic site’s activation. In these instances, reads extending past the intron-exon 
boundary are being spliced at the cryptic site, instead of the natural donor. In particular, samples IV and V both have a statistically significant 
numbers of such reads, 7 (p = 0.01) and 5 (p = 0.04), respectively. This is further typified by the corresponding histogram in (D). (C) focuses 
upon exon 8 from (A) and displays the genomic positions 46726908–46726957. Refer to the caption of Figure 4 for IGV graphical element 
descriptions. In the histograms, arrowheads denote numbers of reads in the variant-containing files. The bottom of the plots provide p-values 
for each respective arrowhead. Statistically significant p-values and their corresponding arrowheads are denoted in red.
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tumours, two had significant levels of junction-spanning intron 
inclusion, and one showed statistically significant read-abundance-
based intron inclusion. Details for all of the aforementioned vari-
ants, including a summary of read counts pertaining to each relevant 
splicing consequence, for experimental versus control samples, are 
provided in Table 2.
Discussion
We have implemented Veridical, a software program that automates 
confirmation of mRNA splicing mutations by comparing sequence 
read-mapped expression data from samples containing variants that 
are predicted to cause defective splicing with control samples lack-
ing these mutations. The program objectively evaluates each muta-
tion with statistical tests that determine the likelihood of and exclude 
normal splicing. To our knowledge, no other software currently 
validates splicing mutations with RNA-Seq data on a genome-wide 
scale, although many applications can accurately detect conven-
tional alternative splice isoforms (i.e.29). Veridical is intended for 
use with large data sets derived from many samples, each contain-
ing several hundred variants that have been previously prioritized as 
likely splicing mutations, regardless of how the candidate mutations 
are selected. It is not practical to analyze all variants present in an 
exome or genome, rather only a filtered subset, due to the extensive 
computations required for statistical validation. As such, Veridical 
is a key component of an end-to-end, hypothesis-based, splicing 
mutation analysis framework that also includes the Shannon splic-
ing mutation pipeline10 and the Automated Splice Site Analysis and 
Exon Definition server5.
There is a trade-off between lengthy run-times and statistical robust-
ness of Veridical, especially when there are either a large number of 
variants or a large number of RNA-Seq files. As with most statistical 
methods, those employed here are not amenable to small sample 
sets, but become quite powerful when a large number of controls 
are employed. In order to ensure that mutations can be validated, 
we recommend an excess of control transcriptome data relative to 
those from samples containing mutations (> 5 : 1), regardless of the 
computational expense. We do not recommend the use of a single 
control to corroborate a sample containing a putative mutation. Not 
surprisingly, we have found that junction-spanning reads have the 
greatest value for corroborating cryptic splicing and exon skipping. 
Even a single such read is almost always sufficient to merit the vali-
dation a variant, provided that sufficient control samples are used. 
For intron inclusion, both junction-spanning and read-abundance-
based reads are useful and a variant can readily be validated with 
either, provided that the variant-containing experimental sample(s) 
show a statistically significant increase in the presence of either 
form of intron inclusion corroborating reads.
Veridical is able to automatically process variants from multiple 
different experimental samples, and can group the variant informa-
tion if any given mutation is present in more than one sample. The 
use of a large sample size allows for robust statistical analyses to be 
performed, which aid significantly in the interpretation of results. 
The main utility of Veridical is to filter through large data sets of 
predicted splicing mutations to prioritize the variants. This helps 
to predict which variants will have a deleterious effect upon the 
protein product. Veridical is able to avoid reporting splicing changes 
that are naturally occurring through checking all variant-containing 
and non-containing control samples for the predicted splicing con-
sequence. In addition, running multiple tumour samples at once 
allows for manual inspection to discover samples that contained the 
alternative splicing pattern, and consequently, permits the identifi-
cation of DNA mutations in the same location which went unde-
tected during genome sequencing.
The statistical power of Veridical is dependent upon the quality of the 
RNA-Seq data used to validate putative variants. In particular, a lack 
of sufficient coverage at a particular locus will cause Veridical to be 
unable to report any significant results. A coverage of at least 20 reads 
should be sufficient. This estimate is based upon alternative splicing 
analyses in which this threshold was found to imply concordance 
with microarray and RT-PCR measurements30–33. There are many 
potential legitimate reasons why a mutation may not be validated: 
(a) nonsense-mediated decay may result in a loss of expression of 
the entire transcript, (b) the gene itself may have multiple paral-
ogs and reads may not be unambiguously mapped, (c) other non-
splicing mutations could account for a loss of expression, and (d) 
confounding natural alternative splicing isoforms may result in a 
loss of statistical significance during read mapping of the control 
samples. The prevalence of loci with insufficient data is dependent 
upon the coverage of the sequencing technology used. As sequenc-
ing technologies improve, the proportion of validated mutations is 
expected to increase. Such an increase would mirror that observed 
for the prevalence of alternative splicing events34. It is important to 
note that acceptance of the null hypothesis, due to an absence of 
evidence required to disprove it, does not imply that the underlying 
prediction of a mutation at a particular locus is incorrect, but merely 
that the current empirical methods employed were insufficient to 
corroborate it.
While there is considerable prior evidence for splicing mutations 
that alter natural and cryptic splice site recognition, we were some-
what surprised at the apparent high frequency of statistically sig-
nificant intron inclusion revealed by Veridical. In fact, evidence 
indicates that a significant portion of the genome is transcribed34, 
and it is estimated that 95% of known genes are alternatively 
spliced30. Defective mRNA splicing can lead to multiple alterna-
tive transcripts including those with retained introns, cassette 
exons, alternate promoters/terminators, extended or truncated 
exons, and reduced exons35. In breast cancer, exon skipping and 
intron retention were observed to be the most common form of 
alternative splicing in triple negative, non-triple negative, and 
HER2 positive breast cancer36. In normal tissue, intron retention 
and exon skipping has been predicted to affect 2572 exons in 2127 
genes and 50 633 exons in 12 797 genes, respectively37. In addition, 
previous studies suggest that the order of intron removal can influ-
ence the final mRNA transcript composition of exons and introns38. 
Intron inclusion observed in normal tissue may result from those 
introns that are removed from the transcript at the end of mRNA 
splicing. Given that these splicing events are relatively common 
in normal tissues, it becomes all the more important to distinguish 
expression patterns that are clearly due to the effects of splicing 
mutations — one of the guiding principles of the Veridical method.
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Table 2. Examples of variants validated by Veridical. Header abbreviations Chr, Cv, Cs, #, SC, and ET, denote chromosome, variant coordinate, splice site coordinate, 
sample number (where applicable), splicing consequence, and evidence type, respectively. Headers containing R with some subscript denote numbers of validated 
reads for the specified variant’s splicing consequence(s) and evidence type(s). RE denotes reads within variant-containing tumour samples. RT and RN denote control samples, 
for tumours and normal cells, respectively. Rμ is the per sample mean of RT and RN. Splicing consequences: CS denotes cryptic splicing, ES denotes exon skipping, and II 
denotes intron inclusion. Evidence types: JS denotes junction-spanning and RA denotes read-abundance.
Gene Chr Cv Cs Variant Type Initial Ri Final Ri ΔRi # SC ET p-value RE RT RN Rμ Figure
HMMR chr5 162905690 162905689 G/T Leaky 12.83 10.67 -2.16 ES JS <  0.01 5 11 0 0.020 [4],[5]
II RA 0.04 14 2133 103 4.051
PTEN chr10 89711873 89711874 A/G Inactivating 12.09 -2.62 -14.71 ES JS <  0.01 32 975 386 2.466 [6(A)]
TMTC2 chr12 83359523 83359524 G/A Inactivating 1.74 -1.27 -3.01 II JS <  0.01 22 2241 383 4.754 [6(B)]
II JSwM < 0.01 22 0 1 0.002
II RA < 0.01 65 7293 1395 15.739 [6(C)]
AGRN chr1 985377 985376 C/T Cryptic -2.24 4.79 7.03 CS JS <  0.01 34 97 23 0.217 [6(D)] 
RAD54L chr1 46726876 46726895 G/T Cryptic 13.4 14.84 1.44 I II JS N/A 0 645 58 1.274 [7]
II RA 0.54 3 2171 290 4.458
II II JS 0.51 1 645 58 1.274
II RA 0.33 6 2171 290 4.458
III II JS N/A 0 645 58 1.274
II RA 0.33 6 2171 290 4.458
IV II JS 0.01 7 645 58 1.274
II RA 0.05 15 2171 290 4.458
V II JS 0.04 5 645 58 1.274
II RA N/A 0 2171 290 4.458
VI II JS N/A 0 645 58 1.274
II RA N/A 0 2171 290 4.458
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Veridical is an important analytical resource for unsupervised, thor-
ough validation of splicing mutations through the use of compan-
ion RNA-Seq data from the same samples. The approach will be 
broadly applicable for many types of genetic abnormalities, and 
should reveal numerous, previously unrecognized, mRNA splicing 
mutations in exome and complete genome sequences.
Data availability
figshare: Input, output, and explanatory files for Veridical, http://
dx.doi.org/10.6084/m9.figshare.89497139.
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Veridical variant input format
This input format most easily accepts formatted output from the 
Shannon Pipeline. In particular, all variants of interest should be 
concatenated into a single file. Once a, tab-delimited, concatenated 
file has been generated, it can easily be formatted correctly by using 
FilterShannonPipelineResults.pl. One can also manu-
ally ensure the following: the header line has no quotation marks or 
special characters, empty columns have been replaced by a period (.) 
and each variant line contains only a single gene (comma-delimited 
gene lists must be split such that there is only one gene per line). If 
one wishes Veridical to consider variants pertaining to more than 
one experimental sample, a comma-delimited list of experimental 
samples, in the form of BAM file names, must be provided as the 
key column. The key column must always contain at least one file 
name that is present as the base name of one of the files listed in the 
BAM file list that must be passed to Veridical.
Alternatively, one can prepare the input format as follows. The header 
must contain at least the following, case-insensitive, values to which 
the file’s columns must adhere to: chromosome, splice&coordinate, 
strand, type, gene, location, location_type, heterozygosity, variant, 
input, key. The column headers need only contain the given text (i.e. 
a column labeled gene_name would be sufficient to satisfy the 
above requirement for a “gene” column). Column headers with am-
persands (&) denote that all words joined by this symbol must be pre-
sent for that column (i.e. Splice_site_coordinate satisfies 
the “splice&coordinate” requirement). The order of the columns is 
immaterial. The input column can contain any identifier for the vari-
ant and need not be unique. The location column specifies if the 
site is natural or cryptic. For Veridical, all that matters is that cryptic 
variants contain the word “cryptic” as part of their value in this col-
umn and that non-cryptic variants do not. The location_type 
column is only used for cryptic variants and specifies if the variant 
is intronic or exonic. It is not currently used by the program. This 
column must be present but can always be set to null (i.e.).
A few rows from a sample variant file is provided below (text 
wrapped for readability):
Chromosome Splice_site_coordinate Strand  
Ri-initial Ri-final ΔRi Type Gene_Name  
Location Location_Type Loc._Rel._to_exon 
Dist._from_nearest_nat._site 
Loc._of_nearest_nat._site 
Ri_of_nearest_nat Cryptic_Ri_rel._nat. 
rsID Average_heterozygosity 
Variant_coordinate Input_variant Input_ID
RNASeqDirectory_ID RNA_Seq_BAM_ID_KEY  
chr10 89711874 + 12.09 -2.62 -14.71
ACCEPTOR PTEN NATURALSITE . . . . . . . 
. 89711873 A/G ID1 dir file  
chr10 89712017 + 5.18 -1.85 -7.03 DONOR 
PTEN NATURALSITE . . . . . . . . 89712018
T/C ID1 dir file 
chrX 9621719 + -4.78 2.25 7.03 DONOR
TBL1X CRYPTICSITE EXONIC . 11 9621730 2.24 
GREATER . . 9621720 C/T ID1 dir file
Veridical exome annotation input format
This input format can be generated via 
ConvertToExomeAnotation.pl. The file must be 
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tab-delimited, excepting its header, which must be comma-delim-
ited. It must have the following, case-insensitive, header columns, 
to which its data must adhere: transcript, chromosome, exon chr 
start, exon chr end, exon rank, gene. The column headers need only 
contain the given text (i.e. a column labeled gene_name would 
be sufficient to satisfy the above requirement for a “gene” column). 
The order of the columns is immaterial.
A few rows from a sample exome annotation file is provided below 
(text wrapped for readability):
Transcript ID,ID,ID,Chromosome Name,Strand,
Exon Chr Start,Exon Chr End,
Exon Rank in Transcript,Transcript Start,
Transcript End, Associated Gene Name
NM_213590 NM_213590 NM_213590 chr13 + 
50571142 50571899 1 50571142 50592603
TRIM13
NM_213590 NM_213590 NM_213590 chr13 + 
50586070 50592603 2 50571142 50592603 
TRIM13
NM_198318 NM_198318 NM_198318 chr19 +
50180408 50180573 1 50180408 50191707
PRMT1
Veridical output
If a variant contains any validating reads, Veridical outputs the vari-
ant in question, along with some summary information and a table 
specifying the numbers of each validating read type detected for 
both the experimental and control samples. Within the output of 
Veridical, the phrase: “Validated (x) variant n times” means that 
the variant was validated mainly for splicing consequence x and 
has n validating reads. The variant will only appear within the 
*.filtered output file if the p-value for either junction-spanning 
or read-abundance-based reads for splicing consequence x was sta-
tistically significant (defined, by default, as: p < 0.05). After the 
variant being validated is provided, along with its primary pre-
dicted splicing consequence, the output is divided into two sections 
with identical contents: one for the experimental sample(s) and 
another for control samples. The summary enumerates the num-
ber of reads of each splicing consequence, partitioned by evidence 
type (junction-spanning or read-abundance-based), and by sample 
type (tumour or normal for control samples, and only tumour for 
experimental samples). A table describing the number of each read 
type for every file follows this summary. An example of this out-
put, for the variant within RAD54L, as shown by Figure 7 and the 
last portion of Table 2, is provided. While Veridical outputs this as 
plain text, with the table in a tab-delimited format, we provide this 
output as an Excel document with descriptions of the meaning of 
each table heading, to clarify the presentation of the data. All input 
and output files for the five variants presented are provided. 
VeridicalOutExample.xls contains the output 
for the variant within RAD54L, along with descriptions of 
the terms used and the output format. all.vin contains the 
input variant file. allTumoursBAMFileList.txt and 
allNormalsBAMFileList.txt are the BAM file lists 
for tumour and normal samples, respectively. all.vout con-
tains the Veridical output. The exome file can be retrieved using 
ConvertToExomeAnnotation.pl, available with the other 
programs at: www.veridical.org. The BAM file lists contain the 
TCGA file UUID, followed by a slash, followed by the file name. 
The RNA-Seq data itself can be downloaded from TCGA at: https://
tcga-data.nci.nih.gov/tcga/.
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YJ Transformed
Figure S1. Histogram and embedded Q-Q plots portraying the difference between untransformed and Yeo-Johnson (YJ) transformed 
data. The plots depict intron inclusion for the inactivating mutation (chr12:83359523 G>A) within TMTC2, as shown in Figure 6(B) and 6(C). 
The arrowheads denote the number of reads in the variant-containing file, which is, in all cases, more than observed in the control samples 
(p < 0.01). The figure legend for all panels is provided in (G), which shows that blue and red plot elements correspond to untransformed 
data, while yellow and purple correspond to YJ transformed elements. Dotted lines in the Q-Q plots are lines passing through the first 
and third quantiles for a normal reference distribution. (A), (C), and (E) show junction-spanning based reads, while (B), (D), and (F) show 
read-abundance-based reads. (A)-(B) depict tumour sample distributions, (B)-(C) depict normal sample distributions, and (E)-(F) depict 
combined tumour and normal sample distributions. This figure is demonstrative of the general trend we have observed. Only data from normal 
samples resemble a Gaussian distribution and the YJ transformation greatly improves the Gaussian nature of all distributions.
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 Peter Robinson
Institute for Medical Genetics, Universitätsklinikum Charité, Berlin, Germany
Approved: 18 March 2014
 18 March 2014Referee Report:
This paper from the Rogan group presents a methodology for validation of DNA sequencing variants that
alter mRNA splicing. While variants of the most conserved splice site nucleotides at the intron-exon
boundary can be predicted to cause splice defects with high reliability, it remains difficult to predict
whether variants deeper in the intron or those that potentially affect exonic splicing enhancers actually
cause splice defects. RNA-seq data, when coupled with variant data, potentially provide a means of
correlating variation data with observations of (mis-)splicing patterns.
 
The program fulfils an important need in the community, the results appear promising and will be of
special interest to groups performing RNA-seq analysis in medical settings. I have only some minor
suggestions that the authors may like to consider.
 
 
Suggestions:
The explanation of the methodology is relatively difficult to follow, and I wonder if it might not be
better to simplify Figures 1 and 2 for didactic sake. For instance, in Figure 1A, it is unclear where
the location of variant  is. Does the curved line mean that it could be anywhere in the middle C
exon?  Also, I assume that exons are being shown in blue and reads shown in gray? 
Also, the legend text is overly complicated:  >  swap  and . While aficionados of first orderD E D E
logic will follow without problems, I would suggest that it would be better for didactic purposes to
delete this and to implicitly assume that <  for the sake of this figure. Figure 1B is confusing atD E
this point in the manuscript because the motivation for switching the variable , , , and  is notA B D E
yet clear. On the other hand, panel C and panel D are trivial and do not add anything. I would
suggest using Figure 1 to provide one concrete example one a simple level, and stating in the text
that the variables are to be switched if the candidate mutation is located on the other side of the
exon. 
Also, the explanations of the method that are couched in first order logic-like notation are difficult to
follow, because it is not stated whether the variant  can precede the start of the read (in whichC
case  would be negative). The subscripts for  in turn have the subscript s  but the variable  inC-S r 1 S
the formula does not. 
Although in the end, I think I follow the overall method, the reader is forced to make arbitrary
assumptions in order to interpret the formulae being used to explain the method. A similar
comment pertains to the flow chart in Figure 2.
Therefore, I would suggest the authors take some pains to improve the clarity of the explanation of
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Therefore, I would suggest the authors take some pains to improve the clarity of the explanation of
the method. I would suggest that they show one of two concrete examples and provide English
language specifications of the FOL-like formulae that describe the partitioning of reads.
 
I am a little unclear on the use of control samples vs experimental samples. Assuming the
experimental samples come from different individuals, what is the reason to assume that they will
have the same distribution of splice mutations?  And given that one finds dozens of splice variants
in normal individuals, what exactly is meant by a control sample? Will control samples not also
have lots of splice mutations? How does the method deal with this? And if we are dealing with
cancer samples, why not user a paired control to detect cancer-specific mutations? In light of this,
the statement "Maximizing the set of control samples, while computationally more expensive,
 does not appear to be supported byincreases the statistical robustness of the results obtained.",
evidence presented in the manuscript.
 
It would be interesting to see a comparison of the distribution of  values and results of Veridical Ri
analysis?
 
How does Veridical decide which sequence variant is causative if there are multiple variations
located in the vicinity of a given mis-spliced exon? 
 
The mutation nomenclature chr1:985377 C>T should not have a space between the position and
the nucleotides.
 
It is unclear to me why a linear regression model was used to show the performance of the method.
The authors could provide timings from real runs.
 
It would be interesting to see a plot on the relationship of the p-values called by Veridical and the
sequencing depth covered. The authors state "In particular, a lack of sufficient coverage at a
particular locus will cause Veridical to be unable to report any significant results. A coverage of at
, but they do not provide evidence for this assertion. This is anleast 20 reads should be sufficient."
important question given that low-expressed genes are thus likely to be systematically
under-represented in the results of Veridcal, and this should be commented on somewhere in the
paper.
 
It would be good if the authors provided Sanger validation of at least some of the mis-splicing
events reported in the paper.
 
The input format for Veridical is described as "This input format most easily accepts formatted
 Why not allow VCF files and filter them for potential spliceoutput from the Shannon Pipeline."
variants informatically prior to Veridcal analysis? It was unclear to me how the variants are to be
selected and whether Veridical can be easily used outside of the Shannon pipeline?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
 Liliana Florea
McKusick-Nathans Institute of Human Genetics, Johns Hopkins University, Baltimore, MD, USA
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The authors describe a method and the associated software, Veridical, for assessing the effects on
pre-mRNA splicing of predicted splicing-affecting mutations. To do so the program compares splicing
effects, measured by the supporting read counts, in variant-containing (disease) samples against a
distribution derived from very large numbers of 'normals', either normal tissue from the same individual or
samples from healthy individuals.
The idea is ingenious and novel as applied to mutations affecting splicing, although not in general (see 
 [ ], which exploits the availability of large numbers of samples to identify likelyVAAST Yandell et al. 2011
deleterious variants; it is also the premise for the  and  projects). The software isHapMap 1000 Genomes
fast and practical, being able to test thousands of variants in hundreds of samples within hours. This is the
first software of its kind, and if accurate it will be a very valuable resource for clinical genomics.
That being said, while the article provides proof-of-concept and clearly demonstrates the potential of the
tool with specific examples, there are several missing pieces that are needed to provide the readers with
a view of its overall performance and limitations and to help them use it effectively.
Major comments:
The article shows numerous positive examples, however there is no indication of the tool's
performance in general. The authors should include the results from running the tool on a full data
set, to give potential users an idea of the expected outcome.
Also, several other tools (e.g., , , ) have been developed for the relatedMATS Miso SpliceTrap
problem of discovering alternative splicing events and comparing them among samples. MATS in
particular, allows differential splicing analyses with multiple replicates. Ideally the paper would
include a comparison with MATS on the data set analyzed; this comparison is informative even if
MATS is used with only a subset of the samples.
 
The method uses the YJ-transformed distribution of supporting read counts across the 'normals' to
determine a p-value for the variant, and thus judge its significance and impact on splicing. This is
an interesting concept that assumes that with large numbers of 'normals' sample and batch effects
will even out; hence, large numbers of samples are required to ensure accuracy. Since these are
absolute (non-normalized) counts, however, the method may not work if the variant sample is
obtained with a different method, e.g. by rRNA depletion of total RNA whereas most normal
samples would come from polyA+ libraries. The authors should clearly discuss this and other
possible limitations of their approach.
 
Related to the above, the authors mention on several occasions the difficulty in identifying intron
inclusion (II) events, in particular the large number of false positives. Indeed, IIs are generally
difficult to predict due to the presence of intronic reads ('noise') from unspliced RNA. The levels
can vary from sample to sample and across the genome, depending on the sample preparation,
gene expression level, splicing efficiency, etc. By comparing read counts exclusively among
samples and without taking into account the gene- or genome-level background, Veridical is likely
to produce many false positives.
In particular, the 14 supporting reads in the left intron on Figure 4 seem hardly sufficient to indicate
an II event, all the more as there is a larger number of reads in the neighboring intron (not predicted
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an II event, all the more as there is a larger number of reads in the neighboring intron (not predicted
to be II). The authors should provide other type of evidence for this event.
 
The mathematical formulas for the various classes of supporting reads and their locations (page 4,
continued on page 6) are hard to understand. It would greatly help the readers to include a figure
showing schematically the event and read location with respect to the introns and exons.
Minor comments:
As another reviewer pointed out, the software requires a registration to obtain a temporary license
for 30 days, after which the availability and terms of use are unclear. This mode of distribution is
not a problem, but the terms should be clearly stated in the manuscript. Also, this is a stand-alone
software and not a web tool as implied by the article.
 
The authors use the term 'cryptic' splice sites throughout the manuscript (I assume meaning
'aberrantly activated'), but some of the events discovered could be alternative exon ends. It would
be helpful to clarify in the context.
This is a potentially very powerful and useful tool. I gave the article an 'Approved with reservation'
because it is critical to include results in the aggregate to complement the showcased examples, as well
as to discuss its limitations. I will gladly change once these few issues are addressed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
 Francesc Xavier Roca
Division of Molecular Genetics and Cell Biology, Nanyang Technological University, Singapore,
Singapore
Approved: 28 January 2014
 28 January 2014Referee Report:
This manuscript describes a new computational tool named Veridical, which detects mutant-allele specific
splicing changes from large RNAseq datasets. This outstanding tool appears very useful to screen the
wealth of transcriptomic data for effects in splicing due to mutations in disease samples, and I think that it
will potentially be of interest for many if not all such RNAseq-based studies. In addition, this could spur
further efforts to derive similar tools with improved efficiencies. Use of this method should help establish
the importance of aberrant splicing in disease as well as the effects of genomic mutations at the RNA
level. I only have two comments, that do not diminish my overall rating of this work as of high value:
 
I personally disagree with the widespread use of the word “validation” in the title, abstract and text.
Authors describe Veridical as a tool to “validate” DNA sequence variants that alter splicing. Indeed,
I think that this tool provides an “association” between the variants and splicing, but not a formal
proof of their connection. As the genomic and RNA samples usually come from different individuals
with many confounding variables, the possibility that the splicing changes arise from factors other
than the individual DNA mutations cannot be ruled out. In other words, changes in the levels of
trans-acting splicing factors could account in part or totally for the splicing changes across
Page 20 of 23
F1000Research 2014, 3:8 Last updated: 18 MAR 2014
F1000Research
1.  
2.  
trans-acting splicing factors could account in part or totally for the splicing changes across
samples. The statistical tests properly conducted in Veridical are designed to minimize such
possibility but do not rule it out. In addition, the inherent noisy nature of RNAseq datasets also
prompts for caution in the conclusions. To me, the direct proof that a DNA mutation changes
splicing of its pre-mRNA can only be provided using minigenes and cell transfection (or in vitro
splicing), in which the substrate sequences and cellular context are under almost absolute control.
Indeed, the Veridical method is reminiscent of GWAS (Genome-Wide Association Studies), in
which the genotype in the DNA, wild-type or mutant, is associated to its phenotype, such as normal
versus disease (or other traits) in GWAS, or normal versus aberrant splicing in this study. Thus, for
me Veridical provides strong associations – but not validations – between DNA mutations and their
effects on splicing.
 
As mentioned briefly at the beginning of Discussion, Veridical has built-in prediction tools to
prioritize the mutations that are more likely to affect splicing, such as those mapping to splice sites.
Even if other sources and tools are cited, a more extensive explanation of these components of
Veridical would help the reader/user.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
 Stefania Bortoluzzi
Department of Biology, University of Padova, Padova, Italy
Approved with reservations: 27 January 2014
 27 January 2014Referee Report:
The paper “ ” byValidation of predicted mRNA splicing mutations using high-throughput transcriptome data
Viner . presents Veridical, a new software for the interpretation and validation of genetic variantset al
identified by DNA sequencing that alter mRNA splicing, leveraging RNA-seq data. The method is based
on statistical comparisons of the normalized read counts of abnormally-spliced RNA species in mutant
versus non-mutant tissues.
 
Actually, the interpretation of genetic variants is a difficult and key issue in current research.
The integration of genomic and transcriptomic data, namely the use of RNA-seq-based transcriptome
characterization as a “molecular phenotype” of cells is useful and meaningful.
 
The software is standalone (not a web-tool) and it is completed by perl scripts, facilitating data
management.
The manuscript declare that “Veridical and its associated software programs are available at:
www.veridical.org”.
Actually, Veridical is commercially available to the scientific community. A trial version lasting 30 days can
be downloaded by the website, but in order to obtain binaries, the website requests a registration with an
institutional email address - they reserve the right to deny access to users who register with third-party
mail servers (Gmail, Yahoo, Hotmail, etc.).
No pricing information is included in the manuscript and, more importantly, in the webpages accessible to
download the software, either before or after registration.
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No pricing information is included in the manuscript and, more importantly, in the webpages accessible to
download the software, either before or after registration.
After downloading the software, I was not able to find R scripts that can be useful to generate some plots,
as indicated in the manuscript.
 
Saying that, the paper is written in a clear language and it is quite complete.
I propose a few revisions that in my opinion can improve the manuscript readability and clarity.
Introduction
 
Line 13 (minor): indicate which hereditary disease (colon cancer?).
 
Methods
 
2  Par, Line 5 (minor): “Maximising” is used, but probably the meaning is “increasing” (the numbernd
of).
 
Figure 1 (major): I feel that the info provided by points C and D is trivial, whilst point A's images,
sentences and legends can be improved. Figure 1 C and D shows simply examples of reads that
are mapped continuously and discontinuously to the reference genome. I think that every potential
user of this type of software known well this concept. On the other hand, regarding A and B (upper
part of the figure) there is not clear correspondence between the text in the legend and the image,
and between the image and the text below (the arch overlap the point A in the figure B, whereas
the text says "reads between A and B").
 
In general, in many cases in the manuscript, the correspondence between legend and figure can
be improved, by indicating more clearly the points specific sentences in the legend refer to.
Regarding this issue, for instance in Figure 4 I can see indicated neither the “exon 12” nor the “14
reads” mentioned in the legend. Please indicate (using colors, boxes, arrows or overlapping text)
key elements in the figure, and revise all figures using the same criterion.
 
Page 5 (minor): Consider revising the sentence “Furthermore, this transformation allowed us to
avoid the use of non-parametric testing, which has its own pitfalls regarding assumptions of the
underlying data distribution”, since normally it is assumed that parametric tests ground on
assumptions on data distributions, but non-parametric tests by definition can be used without
information about data distribution.
 
End of the next paragraph (major): “It is important to realize, therefore, that the p-values given by
Veridical are much more robust when the program is provided with a large number of samples.”
This is a pretty clear concept. Please, indicate a general rule to the user/reader: How many
samples are required? Setting a reasonable minimum can be more useful for experimental design
than saying the larger the sample size the most robust the result.
 
Results
 
I have two important criticisms about the Results section:
The section is not organized in paragraphs, and mixes performance info (run time using different
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The section is not organized in paragraphs, and mixes performance info (run time using different
number of samples and variants) with example results.
 
Not clearly saying how these results were obtained. This is important to guarantee repeatability.
 
(Major) I propose to reorganize the results (considering skipping less important examples; retain
surely Fig. 4 and 6) and insert a first paragraph providing information about the dataset used for
variants validation (how many samples, how many controls) and about the variant calling (BAM
files can be obtained with different settings and criteria and the same apply to calling and filtering of
variants). Moreover, please explain how RNA-seq data are treated, and particularly how they are
normalized to guarantee cross-samples comparability.
 
(Major) Also, a brief discussion about the impact of disease samples not carrying the given
mutation can be useful, as well as regarding the possibility that a tumour sample not carrying the
considered variant can present altered transcriptome since other variants (or factors) impact on the
“molecular phenotype”.
 
Figure 4 (minor): Please comment about the possible existence of intronic transcripts (totally
unknown or also annotated in Ensemble, but not displayed in the more conservative RefSeq
annotations).
 
Figure 5 (minor): Please define better the measure “Read−Abundance Total Intron Inclusion”.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
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